Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2006

01-04-2006 | Erratum

Exserohilum: an emerging human pathogen

Authors: A. Adler, I. Yaniv, Z. Samra, J. Yacobovich, S. Fisher, G. Avrahami, I. Levy

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2006

Login to get access

Excerpt

Due to a typesetting error, the last column was omitted from Tables 1 and 2.
Table 1
Characteristics of patients with invasive Exserohilum infection
Patient no. [ref.]
Age (y)/sex
Exserohilum species
Country/year of report
Underlying disease and predisposing factors
Sites of infection
Therapy (antifungal susceptibility; duration)
Outcome
1 [5]
12/M
rostratum a
Western USA/1980
None
Bone
Surgery, local and systemic AmBc
Cure
2 [6]
20/F
longirostratum b
France/1983
Surgical correction of congenital VSD and AI
Endocarditis, vertebral osteomyelitis
AmB, keto (72 h MFC=1 μg/ml for both; 10 months), surgery
Cure
3 [7]
63/M
rostratum
Israel/1987
AML; antimicrobial and chemotherapy; neutropenia
Skin (cutaneous), nasal mucosa
AmB (2 months)
Cure
4 [8]
5/F
rostratum
Texas, USA/1990
Aplastic anemia; cytotoxic therapy
Paranasal sinuses, soft tissue
AmB (48 h MIC<0.14 μg/ml), itra (48 h MIC<0.02 μg/ml)
Progression; death due to bacterial sepsis
5 [9]
16/M
NR
South Africa/1993
None
Skin (subcutaneous), lung, brain
AmB (total dose 2.5 g), 5-flu
Cure
6 [10]
7/F
rostratum
Texas, USA/1994
Aplastic anemia
Paranasal sinuses, lungs
AmB
Death
7 [11]
41/F
NR
Israel/2004
AML
Paranasal sinuses, lungs
AmB, itra
Failure; death due to bacterial sepsis
8 [12]
8/M
NR
Israel/2003
ALL, antimicrobial and chemotherapy; neutropenia
Skin (cutaneous), Paranasal sinuses, lungs
AmB, itra (5 mos.)
Cure; death due to malignancy and Fusarium infection
9 [PR]
8/F
NR
Israel/2005
ALL; antimicrobial and chemotherapy; neutropenia
Paranasal sinuses, lungs
AmB, vori (9 months), surgery
Cure
10 [PR]
3/F
NR
Israel/2005
ALL; antimicrobial and chemotherapy; neutropenia
Paranasal sinuses, soft palate
AmB, itra (13 months), surgery
Cure
PR present report, VSD ventricular septal defect, AI aortic insufficiency, AmB amphotericin B, keto ketoconazole, MFC minimum fungicidal concentration, 5-flu 5-flucytosine, AML acute myelogenous leukemia, MIC, minimum inhibitory concentration, itra itraconazole, ALL acute lymphoblastic leukemia, vori voriconazole, NR not reported
aIsolate originally reported as Drechslera rostrata
bIsolate originally reported as Drechslera longirostrata
cTherapy was required intermittently for frequent recurrences of the infection up to 8 years after presentation
Table 2
Characteristics of patients with Exserohilum skin and corneal infections
Patient no. [ref.]
Age (y)/sex
Exserohilum species
Country/year of report
Underlying diseases and predisposing factors
Sites of infection
Therapy (antifungal susceptibility; duration)
Outcome
11 [3]
34/F
rostratum
Calif., USA/1986
Cardiac transplantation; immunosuppression
Skin (subcutaneous)
AmB, keto, surgery
Cure
12 [13]
55/F
rostratum
S. Carolina, USA/1987
Fish sting
Skin (subcutaneous)
Surgery, keto (6 weeks)
Cure
13 [14]
3/M
rostratum
Tenn., USA/1991
ALL; antimicrobial and chemotherapy; neutropenia; local cloth tape
Skin (cutaneous)
AmB (24 h MIC=0.39 μg/ml; 1 month), 5-flu (24 h MIC >20 μg/ml; 2 weeks)
Cure
14 [15]
74/M
rostratum
Texas, USA/1991
COPD; steroid therapy
Skin (cutaneous)
Keto+topical clotrimazole (6 weeks)
Cure
15 [16]
63/M
rostratum
Taiwan/1993
Diabetes; local trauma
Skin (subcutaneous)
Keto (3 weeks)
No improvement; death due to bacterial sepsis
16 [16]
31/M
rostratum
Taiwan/1993
Topical steroids for psoriasis
Skin (cutaneous)
Topical bifonazole (2 weeks)
Cure
17 [17]
22/M
rostratum
Va., USA/1993
Superficial lacerations; cocaine use, MOF
Skin (cutaneous)
AmB
Death due to MOF
18 [18]
40/F
rostratum
India/1995
None
Skin (cutaneous)
None
Unknown
19 [19]
NR/NR
rostratum a
Fla., USA/1975
None
Cornea
Topical gentamicin
Cure
20 [20]
40/F
rostratum
India/1991
Rt. eye injury from a paddy leaf
Cornea
Topical keto
No improvement
21 [21]
47/M
longirostratum
Honduras/1994
Left eye struck by unknown foreign body during train riding
Cornea and uvea
Surgery, keto
Cure following enucleation
22 [22]
55/M
rostratum
India/1996
Lash injury to rt. eye by cow’s tail
Cornea
Topical nata + mico (6 weeks)
Cure (vision 6/18)
23 [23]
42/M
rostratum
India/1999
None
Cornea
Surgery, topical keto+nata
Cure (vision 6/18)
24 [24]
18/F
rostratum
India/2004
None
Cornea
topical itra
Cure
AmB, amphotericin B, keto ketoconazole, MIC minimum inhibitory concentration, ALL acute lymphoblastic leukemia, 5-flu 5-flucytosine, COPD chronic obstructive pulmonary disease, MOF multiorgan failure, mico miconazole, NR not reported
aIsolate originally reported as Drechslera halodes
Metadata
Title
Exserohilum: an emerging human pathogen
Authors
A. Adler
I. Yaniv
Z. Samra
J. Yacobovich
S. Fisher
G. Avrahami
I. Levy
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2006
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-006-0121-3

Other articles of this Issue 4/2006

European Journal of Clinical Microbiology & Infectious Diseases 4/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.